Do Kim is a managing director and senior research analyst at Piper Sandler covering the biotechnology sector. Prior to joining Piper Sandler in 2021, he covered biotech for more than 15 years on the sellside and buyside, including at BMO Capital Markets, Nomura Securities, and Safra Asset Management. Before equity research, Kim was a researcher in molecular biology and genetics at the Kennedy Krieger Institute, the pediatric affiliate of Johns Hopkins Hospital, where he co-authored 17 peer-reviewed journal articles. Kim received his bachelor’s degree in Biology from the Johns Hopkins University and an MBA in Finance and Economics from Columbia Business School. He is also a CFA charterholder.